The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 of ab83581 is typically 10-20 ng/ml as measured in a cell proliferation assay using the human growth factor-dependent M-07e cell line.
Concentration information loading...
Shipped at 4°C. After reconstitution store at -20ºC. Avoid freeze / thaw cycles.
Constituents: 10% Trehalose, 1% Human serum albumin
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C. Repeated freeze thawing is not recommended.
C kit ligand
familial progressive hyperpigmentation 2
Mast cell growth factor
MGF stem cell factor
Soluble KIT ligand
steel, mouse, homolog of
Stem cell factor
Stem cell factor precursor
Ligand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.
Hyperpigmentation with or without hypopigmentation, familial progressive Deafness, congenital, unilateral or asymmetric
Belongs to the SCF family.
Acts in the early stages of hematopoiesis.
A soluble form (sKITLG) is produced by proteolytic processing of isoform 1 in the extracellular domain. Found in two differentially glycosylated forms, LMW-SCF and HMW-SCF. LMW-SCF is fully N-glycosylated at Asn-145, partially N-glycosylated at Asn-90, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97 or Asn-118. HMW-SCF is N-glycosylated at Asn-118, Asn-90 and Asn-145, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97. A soluble form exists as a cleavage product of the extracellular domain.
Functional Studies - SCF protein (Active) (ab83581)
Densitometry of protein isoforms visualised by 2-DE. The densitometry scan demonstrates the purified human cell expressed protein exists in multiple isoforms, which differ according to their level of post-translational modification. The triangle indicates the theoretical MW and pI of the protein.
SDS-PAGE - SCF protein (Active) (ab83581)
1D SDS-PAGE of ab83581 before and after treatment with glycosidases to remove oligosaccharides.
Lane 1 – MW markers; Lane 2 – ab83581 ; Lane 3 – ab83581 treated with PNGase F to remove potential N-linked glycans; Lane 4 – ab83581 treated with a glycosidase cocktail to remove potential N- and O-linked glycans. Approximately 5 µg of protein was loaded per lane. Drop in MW after treatment with PNGase F indicates presence of N-linked glycans. A further drop in MW after treatment with the glycosidase cocktail indicates the presence of O-linked glycans. Additional bands in lane 3 and lane 4 are glycosidase enzymes.
SDS-PAGE - SCF protein (Active) (ab83581)
A sample of ab83581 without carrier protein was reduced and alkylated and focused on a 3-10 IPG strip then run on a 4-20% Tris-HCl 2D gel. Approximately 40 µg of protein was loaded. Spot train indicates presence of multiple isoforms of SCF. Spots within the spot train were cut from the gel and identified as SCF by protein mass fingerprinting.
Recombinant human SCF protein (ab83581)参考文献
has not yet been referenced specifically in any publications.